Standard of care treatments for patients with cMEL, cSCC, hnSCC and ACC
Thomas Eigentler, MD, University of Tübingen, Tübingen, Germany, outlines the current first- and second-line treatment options for patients with advanced cutaneous melanoma (cMEL), cutaneous squamous cell carcinoma (cSCC), head and neck squamous cell carcinoma (hnSCC) or adenoid cystic carcinoma (ACC). The standard of care first-line treatment for patients with cMEL consists of anti-PD-1 monotherapy or in combination with ipilimumab. Patients with a BRAF mutation who progress on immunotherapy can receive targeted therapy. However, there is no approved second-line treatment for patients who do not carry BRAF mutations. Patients with cSCC, hnSCC and ACC are treated with anti-PD-1-based therapy in the first-line setting, but there is currently no approved option in the second-line setting. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
-
Category
No comments found